2020 will be a turning point for the U.S. acute migraine market. Three novel therapies\u2014Allergan\u2019s Ubrelvy, Eli Lilly\u2019s Reyvow, and Biohaven\u2019s Nurtec ODT\u2014entered the market in rapid succession, becoming the first novel, migraine-specific therapies to be approved in the acute segment in nearly two decades. Meanwhile a range of additional acute products are advancing through late-phase development. This report assesses how U.S. physicians and payers will react to new, premium-priced brands entering a mostly generic market, and how payer policies will affect physicians\u2019 adoption.<\/p>\n
QUESTIONS ANSWERED<\/strong><\/p>\n PRODUCT DESCRIPTION<\/strong><\/p>\n U.S. Access & Reimbursement<\/em> provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of U.S. payer policy on physician prescribing behavior in the market access environment, including up-to-date analysis of drug coverage and restriction policies and payer and prescriber perspectives on key marketed drugs and receptivity to emerging therapies.<\/p>\n Geography<\/strong><\/p>\n United States.<\/p>\n Primary Research<\/strong><\/p>\n Survey of 100 U.S. physicians (including 50 neurologists and 50 PCPs).<\/p>\n Survey of 31 U.S. managed care organization (MCO) pharmacy directors and medical directors (PDs\/MDs).<\/p>\n Fingertip Formulary<\/strong><\/p>\n Formulary coverage and restrictions data for acute migraine therapies by commercial plans covering approximately 168 million lives nationally.<\/p>\n Key Drugs Covered<\/strong><\/p>\n Reyvow (lasmiditan), Ubrelvy (ubrogepant), Nurtec ODT (rimegepant), Elyxyb, AXS-07, Rizaport, Qtrypta, INP104, STS101, zavegepant (vazegepant), current SoC treatments.<\/p>\n Content Highlights<\/strong><\/p>\n\n
\n